Story perspectives

NHS Approves AbbVie’s Elahere, Boosts Survival to 16.5 Months

6/5/2026

48 4

Summary

NHS England Approves

NHS England approved AbbVie’s mirvetuximab soravtansine (Elahere) for hard-to-treat ovarian, peritoneal and fallopian-tube cancers.
NICE recommended the drug after a trial at eight NHS hospitals showed median overall survival of 16.5 months versus 12.8 months with standard chemotherapy.
The study reported tumour shrinkage of at least 30% in 37% of patients, compared with 16% for chemotherapy.
NHS England estimates the approval could benefit up to 400 patients per year.

Summary

NICE Approves

NICE has declared the therapy cost-effective and approved it for NHS use.
The guidance projects 270 eligible patients in year one, rising to 420 by year three, with eligibility set at >75 % tumour cells expressing folate receptor-?, a marker in 32 % of cases.
Funding will start via the Cancer Drugs Fund and move to commissioning 90 days after guidance, providing benefit for South Asian, Caribbean and African women who receive diagnoses.

1 of 2

NHS England Approves

NHS England approved AbbVie’s mirvetuximab soravtansine (Elahere) for hard-to-treat ovarian, peritoneal and fallopian-tube cancers.
NICE recommended the drug after a trial at eight NHS hospitals showed median overall survival of 16.5 months versus 12.8 months with standard chemotherapy.
The study reported tumour shrinkage of at least 30% in 37% of patients, compared with 16% for chemotherapy.
NHS England estimates the approval could benefit up to 400 patients per year.

1 / 2